Everest Medicines to acquire Kezar Life Sciences for $132.5m.

Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, agreed to acquire Kezar Life Sciences, a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, for $132.5m. "We are glad to form a partnership with Kezar through our cooperation on zetomipzomib, which will add to our existing renal pipeline, and help solidify Everest's leading position in renal and autoimmune diseases in Asia," Rogers Yongqing Luo, Everest Medicines Chief Executive Officer.